Annual EBITDA
-$539.93 M
-$100.09 M-22.75%
December 31, 2022
Summary
- As of March 9, 2025, SRNE annual EBITDA is -$539.93 million, with the most recent change of -$100.09 million (-22.75%) on December 31, 2022.
- During the last 3 years, SRNE annual EBITDA has fallen by -$226.39 million (-72.20%).
- SRNE annual EBITDA is now -2068.17% below its all-time high of $27.43 million, reached on December 31, 2017.
Performance
SRNE EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$101.60 M
+$36.43 M+26.39%
June 30, 2023
Summary
- As of March 9, 2025, SRNE quarterly EBITDA is -$101.60 million, with the most recent change of +$36.43 million (+26.39%) on June 30, 2023.
- Over the past year, SRNE quarterly EBITDA has increased by +$36.43 million (+26.39%).
- SRNE quarterly EBITDA is now -202.61% below its all-time high of $99.02 million, reached on September 30, 2017.
Performance
SRNE Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$532.12 M
+$113.44 M+17.57%
June 30, 2023
Summary
- As of March 9, 2025, SRNE TTM EBITDA is -$532.12 million, with the most recent change of +$113.44 million (+17.57%) on June 30, 2023.
- Over the past year, SRNE TTM EBITDA has increased by +$113.44 million (+17.57%).
- SRNE TTM EBITDA is now -1181.52% below its all-time high of $49.20 million, reached on September 30, 2017.
Performance
SRNE TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
SRNE EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -22.8% | +26.4% | +17.6% |
| 3 y3 years | -72.2% | +26.4% | +17.6% |
| 5 y5 years | -2068.2% | +26.4% | +17.6% |
SRNE EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -22.8% | at low | -213.6% | +52.8% | -21.0% | +17.6% |
| 5 y | 5-year | -93.2% | at low | -1383.7% | +52.8% | -145.0% | +17.6% |
| alltime | all time | -2068.2% | at low | -202.6% | +52.8% | -1181.5% | +17.6% |
Sorrento Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2023 | - | -$101.60 M(-26.4%) | -$532.12 M(-17.6%) |
| Mar 2023 | - | -$138.03 M(-32.6%) | -$645.56 M(+19.6%) |
| Dec 2022 | -$539.93 M(+22.8%) | -$204.93 M(+134.1%) | -$539.93 M(+6.4%) |
| Sep 2022 | - | -$87.55 M(-59.3%) | -$507.27 M(-4.8%) |
| Jun 2022 | - | -$215.05 M(+563.8%) | -$533.04 M(+11.0%) |
| Mar 2022 | - | -$32.40 M(-81.2%) | -$480.16 M(+9.2%) |
| Dec 2021 | -$439.84 M(+57.4%) | -$172.27 M(+52.0%) | -$439.84 M(+30.9%) |
| Sep 2021 | - | -$113.33 M(-30.1%) | -$335.93 M(+10.8%) |
| Jun 2021 | - | -$162.16 M(-2148.8%) | -$303.31 M(+39.7%) |
| Mar 2021 | - | $7.92 M(-111.6%) | -$217.16 M(-23.7%) |
| Dec 2020 | -$279.42 M(-10.9%) | -$68.36 M(-15.3%) | -$284.67 M(+3.3%) |
| Sep 2020 | - | -$80.70 M(+6.2%) | -$275.69 M(+7.2%) |
| Jun 2020 | - | -$76.02 M(+27.6%) | -$257.22 M(+7.2%) |
| Mar 2020 | - | -$59.59 M(+0.4%) | -$239.87 M(-23.5%) |
| Dec 2019 | -$313.54 M(+113.8%) | -$59.38 M(-4.6%) | -$313.54 M(+5.3%) |
| Sep 2019 | - | -$62.23 M(+6.1%) | -$297.72 M(+6.0%) |
| Jun 2019 | - | -$58.67 M(-56.0%) | -$280.92 M(+12.6%) |
| Mar 2019 | - | -$133.26 M(+205.9%) | -$249.40 M(+70.1%) |
| Dec 2018 | -$146.66 M(-634.6%) | -$43.56 M(-4.1%) | -$146.66 M(+4.1%) |
| Sep 2018 | - | -$45.44 M(+67.4%) | -$140.83 M(-3984.9%) |
| Jun 2018 | - | -$27.15 M(-11.0%) | $3.63 M(-80.6%) |
| Mar 2018 | - | -$30.52 M(-19.1%) | $18.67 M(-32.6%) |
| Dec 2017 | $27.43 M(-145.1%) | -$37.73 M(-138.1%) | $27.70 M(-43.7%) |
| Sep 2017 | - | $99.02 M(-918.2%) | $49.20 M(-243.6%) |
| Jun 2017 | - | -$12.10 M(-43.7%) | -$34.26 M(-47.9%) |
| Mar 2017 | - | -$21.49 M(+32.4%) | -$65.80 M(+8.3%) |
| Dec 2016 | -$60.77 M(+966.8%) | -$16.23 M(-204.3%) | -$60.74 M(-6.5%) |
| Sep 2016 | - | $15.56 M(-135.6%) | -$64.98 M(+39.8%) |
| Jun 2016 | - | -$43.64 M(+165.5%) | -$46.49 M(+263.8%) |
| Mar 2016 | - | -$16.43 M(-19.7%) | -$12.78 M(+124.3%) |
| Dec 2015 | -$5.70 M | -$20.46 M(-160.1%) | -$5.70 M(-197.7%) |
| Sep 2015 | - | $34.05 M(-442.9%) | $5.83 M(-116.9%) |
| Jun 2015 | - | -$9.93 M(+6.1%) | -$34.54 M(+8.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2015 | - | -$9.35 M(+4.7%) | -$31.80 M(+0.8%) |
| Dec 2014 | -$31.55 M(+54.9%) | -$8.93 M(+41.3%) | -$31.55 M(-4.7%) |
| Sep 2014 | - | -$6.32 M(-12.1%) | -$33.09 M(+11.2%) |
| Jun 2014 | - | -$7.19 M(-20.9%) | -$29.76 M(+10.0%) |
| Mar 2014 | - | -$9.10 M(-13.2%) | -$27.05 M(+32.8%) |
| Dec 2013 | -$20.37 M(+347.5%) | -$10.47 M(+249.6%) | -$20.37 M(+76.1%) |
| Sep 2013 | - | -$3.00 M(-33.3%) | -$11.56 M(+18.8%) |
| Jun 2013 | - | -$4.49 M(+86.3%) | -$9.73 M(+59.1%) |
| Mar 2013 | - | -$2.41 M(+44.2%) | -$6.12 M(+34.4%) |
| Dec 2012 | -$4.55 M(+47.6%) | -$1.67 M(+43.5%) | -$4.55 M(+26.8%) |
| Sep 2012 | - | -$1.16 M(+33.2%) | -$3.59 M(+16.5%) |
| Jun 2012 | - | -$873.70 K(+3.6%) | -$3.08 M(-5.3%) |
| Mar 2012 | - | -$843.60 K(+19.1%) | -$3.25 M(+5.5%) |
| Dec 2011 | -$3.08 M(+72.4%) | -$708.10 K(+7.8%) | -$3.08 M(+20.6%) |
| Sep 2011 | - | -$656.70 K(-37.2%) | -$2.56 M(+9.3%) |
| Jun 2011 | - | -$1.05 M(+55.5%) | -$2.34 M(+25.5%) |
| Mar 2011 | - | -$672.70 K(+269.0%) | -$1.86 M(+4.2%) |
| Dec 2010 | -$1.79 M(+88.0%) | -$182.30 K(-58.5%) | -$1.79 M(-22.1%) |
| Sep 2010 | - | -$439.10 K(-23.0%) | -$2.30 M(+9.6%) |
| Jun 2010 | - | -$570.20 K(-4.5%) | -$2.10 M(+35.1%) |
| Mar 2010 | - | -$597.20 K(-13.4%) | -$1.55 M(+62.6%) |
| Dec 2009 | -$951.40 K(+3601.9%) | -$689.90 K(+189.0%) | -$954.20 K(+555.4%) |
| Sep 2009 | - | -$238.70 K(+832.4%) | -$145.60 K(+345.3%) |
| Jun 2009 | - | -$25.60 K(-121.6%) | -$32.70 K(+27.2%) |
| Dec 2008 | -$25.70 K(-89.3%) | $118.70 K(-194.4%) | -$25.70 K(-83.1%) |
| Sep 2008 | - | -$125.80 K(+2229.6%) | -$151.80 K(+314.8%) |
| Jun 2008 | - | -$5400.00(-59.1%) | -$36.60 K(-16.4%) |
| Mar 2008 | - | -$13.20 K(+78.4%) | -$43.80 K(-81.8%) |
| Dec 2007 | -$240.60 K(-45.2%) | -$7400.00(-30.2%) | -$240.50 K(+3.2%) |
| Sep 2007 | - | -$10.60 K(-15.9%) | -$233.10 K(+4.8%) |
| Jun 2007 | - | -$12.60 K(-94.0%) | -$222.50 K(+6.0%) |
| Mar 2007 | - | -$209.90 K | -$209.90 K |
| Dec 2006 | -$439.30 K | - | - |
FAQ
- What is Sorrento Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Sorrento Therapeutics?
- What is Sorrento Therapeutics annual EBITDA year-on-year change?
- What is Sorrento Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Sorrento Therapeutics?
- What is Sorrento Therapeutics quarterly EBITDA year-on-year change?
- What is Sorrento Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Sorrento Therapeutics?
- What is Sorrento Therapeutics TTM EBITDA year-on-year change?
What is Sorrento Therapeutics annual EBITDA?
The current annual EBITDA of SRNE is -$539.93 M
What is the all time high annual EBITDA for Sorrento Therapeutics?
Sorrento Therapeutics all-time high annual EBITDA is $27.43 M
What is Sorrento Therapeutics annual EBITDA year-on-year change?
Over the past year, SRNE annual EBITDA has changed by -$100.09 M (-22.75%)
What is Sorrento Therapeutics quarterly EBITDA?
The current quarterly EBITDA of SRNE is -$101.60 M
What is the all time high quarterly EBITDA for Sorrento Therapeutics?
Sorrento Therapeutics all-time high quarterly EBITDA is $99.02 M
What is Sorrento Therapeutics quarterly EBITDA year-on-year change?
Over the past year, SRNE quarterly EBITDA has changed by +$36.43 M (+26.39%)
What is Sorrento Therapeutics TTM EBITDA?
The current TTM EBITDA of SRNE is -$532.12 M
What is the all time high TTM EBITDA for Sorrento Therapeutics?
Sorrento Therapeutics all-time high TTM EBITDA is $49.20 M
What is Sorrento Therapeutics TTM EBITDA year-on-year change?
Over the past year, SRNE TTM EBITDA has changed by +$113.44 M (+17.57%)